Clinical Findings Presentations, Stock Price Movements, and Addition to Indexes - Research Report on Acceleron, AcelRx, Antares, Chelsea Therapeutics, and Clovis

Editor Note: For more information about this release, please scroll to bottom.

Jan 06, 2014, 08:00 ET from Analysts' Corner

NEW YORK, January 6, 2014 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Acceleron Pharma, Inc. (NASDAQ: XLRN), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Antares Pharma Inc. (NASDAQ: ATRS), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), and Clovis Oncology, Inc. (NASDAQ: CLVS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Acceleron Pharma, Inc. Research Report

On December 20, 2013, Acceleron Pharma, Inc. (Acceleron) announced that it has been selected to be added to the Russell 2000®, Russell 3000®, and Russell Global® Indexes. The Company stated that its addition to the Indexes is part of Russell Investments' quarterly addition of select IPO companies. Acceleron added that Russell 2000 Index measures the performance of the small-cap segment of the market and is a subset of the Russell 3000, which also serves as the U.S. component to the Russell Global Index. The Full Research Report on Acceleron Pharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/4b10_XLRN

--

AcelRx Pharmaceuticals, Inc. Research Report

On December 31, 2013, AcelRx Pharmaceuticals Inc. (AcelRx) stock rose 7.51% to end the day at $11.31, compared to the previous closing price of $10.52. The Company's stock climbed 5.70% over the past three trading days, compared to the Dow Jones Industrial Average which gained 0.59% during the same trading period. The Full Research Report on AcelRx Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/1454_ACRX

--

Antares Pharma Inc. Research Report

On December 31, 2013, Antares Pharma Inc. (Antares) stock rose 3.95%, to end the day at $4.47. The Company's stock gained 7.71% during the last three trading sessions, compared to the Dow Jones Industrial Average which went up by 0.59% over the same trading period. The Full Research Report on Antares Pharma Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/2353_ATRS

--

Chelsea Therapeutics International Ltd. Research Report

On December 31, 2013, Chelsea Therapeutics International Ltd. (Chelsea Therapeutics) stock closed the day at $4.44, a 3.74% rise over the previous day's closing price at $4.28. The Company's stock gained 0.68% over the past three trading days, compared to the Dow Jones Industrial Average which rose 0.59% over the same trading period. The Full Research Report on Chelsea Therapeutics International Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/c6ad_CHTP

--

Clovis Oncology, Inc. Research Report

On December 23, 2013, Clovis Oncology, Inc. (Clovis) announced that an abstract titled "First-in-Human Evaluation of CO-1686, an Irreversible, Highly Selective Tyrosine Kinase Inhibitor of Mutations of EGFR (Activating and T790M)" discussing the findings from the ongoing Phase I portion of the Phase I/II clinical study of CO-1686 has been accepted for Proffered Paper (Oral) presentation during the 4th European Lung Cancer Conference, to be held on March 26-29, 2014 in Geneva, Switzerland. Clovis stated that CO-1686 is the Company's new, oral, targeted covalent (irreversible) inhibitor of mutant forms of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer (NSCLC) in patients with initial activating EGFR mutations as well as the dominant resistance mutation T790M. The Company added that it plans to describe its clinical development plan for CO-1686 at the JP Morgan Healthcare Conference in mid-January and at the Clovis Oncology R&D Day for Investors and Analysts to be held on January 27, 2014. The Full Research Report on Clovis Oncology, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/6a2a_CLVS

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner